Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study

(2013) Lamiae Grimaldi-Bensouda et al.   DIABETES CARE

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

(2012) G. B. Bolli et al.   DIABETES CARE

Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins?: A French nationwide cohort study based on national administrative databases

(2012) J.-P. Fagot et al.   DIABETES CARE

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study

(2011) P. Lucidi et al.   DIABETES CARE

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites

(2010) Mark R. Sommerfeld et al.   PLoS One